Lilly and Viking Just Showed the Obesity Market’s Next Phase — and It’s Not About Pounds

Life Science

Competition Fears Are Overblown, and Eli Lilly’s Growth Engine Remains Strong

Life Science

AstraZeneca to Invest $2 Billion in Summit Therapeutics, Backing China-Licensed Cancer Drug

Life Science

Kodiak Sciences Stock Soars as Trial Data Boosts Market Confidence

Life Science

Summit Secures $2 Billion Investment From AstraZeneca, and the Two Parties Will Jointly Develop Anti-Cancer Drugs

Life Science

Down 35% This Year, Alnylam Still Has Wall Street Calling 44% Upside

Life Science

Lilly Accelerates M&A Push, Targeting Scientific “White Spaces”

Life Science

STAAR Surgical Announces $50 Million Buyback Plan, Stock Soars More Than 7% on Friday

Life Science

ByteDance’s Anew Labs Emerges With $1.5B Valuation, Stirring New Questions Over AI Drug Discovery

Life Science

Revolution Medicines Receives FDA Breakthrough Designation, Royalty Pharma Offers a Diversified Investment Path

Life Science

BMY vs. JNJ: Low Valuation and High Yield or High Profit and Steady Growth?

Life Science

AI Finds New Clues for Gene Editing, but It Is Still Far from a “New CRISPR”

Life Science

Positive VK2735 Clinical Data: Can Viking Therapeutics Displace Eli Lilly and Novo Nordisk?

Life Science

Iambic Therapeutics Files for U.S. IPO, Adding Another AI Drug-Discovery Startup to Nasdaq Pipeline

Life Science, Technology

Johnson & Johnson Accelerates Divestiture of DePuy Synthes, Investors Optimistic About Streamlined Strategy

Life Science